We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00051181
First Posted: January 7, 2003
Last Update Posted: August 5, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Alcon Research
  Purpose
To demonstrate that the intraocular pressure(IOP)-lowering efficacy of Travoprost (0.004%) is equal or better than that of Latanoprost 0.005% in patients with chronic angle-closure glaucoma.

Condition Intervention Phase
Glaucoma, Angle-Closure Ocular Hypertension Drug: Travoprost (0.004%) Drug: Latanoprost (0.005%) Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma.

Resource links provided by NLM:


Further study details as provided by Alcon Research:

Study Start Date: January 2000
Study Completion Date: June 2003
Primary Completion Date: June 2003 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
Adult patients of any race and either sex with chronic angle-closure glaucoma.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00051181


Locations
United States, Texas
Asia
Fort Worth, Texas, United States
Australia
Australia
Sidney, Australia
Sponsors and Collaborators
Alcon Research
  More Information

ClinicalTrials.gov Identifier: NCT00051181     History of Changes
Other Study ID Numbers: C-01-38
First Submitted: January 3, 2003
First Posted: January 7, 2003
Last Update Posted: August 5, 2008
Last Verified: August 2008

Keywords provided by Alcon Research:
Glaucoma
POAG
OAG
OHT

Additional relevant MeSH terms:
Glaucoma
Ocular Hypertension
Glaucoma, Angle-Closure
Eye Diseases
Latanoprost
Travoprost
Antihypertensive Agents